Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases

Abstract

This large study demonstrated that early dynamic changes in the vascularity of liver metastases evaluated by quantified CEUS are associated with outcome in patients receiving first-line bevacizumab-based treatment for metastatic CRC.

Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer

“…Data were prospectively collected in a French multicenter, nonrandomized study designed to evaluate whether contrast-enhanced ultrasound imaging predicts the efficacy of bevacizumab on colorectal cancer with hepatic metastases (mCRC) (STIC-Avastin, NCT00489697) [33], sponsored by the University Hospital of Tours. This study was in accordance with the code of ethics of the World Medical Association.…”

“…CT analysis of the lumbar (L3) muscle area has been thoroughly validated [35][36][37]. Assessments were made on CT images as specified in the study protocol, at baseline (within 2 weeks of before and at two months after the start of bevacizumab-based chemotherapy [33]). One axial image at the 3rd lumbar vertebra was selected for analysis of total muscle and fat crosssectional areas (cm 2 ) [36][37][38][39].…”

Perfusion Quantification of Liver Metastases of Colorectal Cancer Treated with Anti-angiogenic-Based Therapy: Assessment of Intra- and Inter-observer Reproducibility of Parameters in Three Regions of Interest Outlining Lesions

“…Patients were included among the 137 included in a multicenter, prospective, interventional cohort study designed to evaluate the usefulness of quantitative DCEUS for early evaluation of tumor response to bevacizumab in metastatic colorectal cancer (NCT00489697) (Tranquart et al 2017). First, patients with available DCEUS exams at both D0 and D15, and whose exam quality was sufficient to perform correct quantification (meaning for example no technical problem or lesion's motion within the scanning plane allowing correct motion compensation) were selected.…”

“…The use of bevacizumab (Avastin, Genentech Inc., South San Francisco, California), an anti-VEGF antibody, is associated with a significant increase in progression-free survival of patients with metastatic colorectal cancer (Hurwitz et al 2004). Since its introduction and approval, several imaging techniques have been explored to improve the assessment of its therapeutic efficacy including quantitative imaging (Coenegrachts et al 2012;De Bruyne et al 2012;Morgan et al 2003;Schirin-Sokhan et al 2012;Tranquart et al 2017;Wu et al 2017). Among these techniques, quantitative dynamic contrast-enhanced ultrasonography (DCEUS) has already demonstrated its ability to improve the follow-up of various types of tumors treated with antiangiogenic agents by predicting the efficacy or the lack of efficacy of such antiangiogenic therapies (Lassau et al 2006;Lassau et al 2010;Lassau et al 2011;Lassau et al 2014;Schirin-Sokhan et al 2012;Tranquart et al 2017;Wu et al 2017).…”

Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy

“…Contrastenhanced liver ultrasound has been the most studied modality in metastatic colorectal patients receiving first-line bevacizumab-based treatment. Several haemodynamic parameters were found to correlate with response and/or survival rates, but, most of the time, only in a small sample of patients and with the lack of control group without anti-angiogenic therapies [24][25][26] .…”